Katsunori Ohnishi
Hokkaido University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Katsunori Ohnishi.
Lupus | 1993
Yoshinori Miyoshi; Tatsuya Atsumi; Hirohiko Kitagawa; Nobutaka Ogura; Yoshiharu Amasaki; Akito Tsutsumi; Katsunori Ohnishi; Atsushi Fujisaku; Akira Sagawa; Takao Koike
A 42-year-old Japanese woman with systemic lupus erythematosus (SLE) developed Parkinsonian-like movements. Steroid pulse therapy was most effective and additional anti-Parkinsonian drugs were not required. Although psychosis, seizures and meningitis are common central nervous system (CNS) manifestations in SLE patients, Parkinsonian-like symptoms are extremely rare. The putative genesis and treatment of CNS lupus are discussed.
Lupus | 1995
Tatsuya Atsumi; Akira Sagawa; S. Jodo; Yoshiharu Amasaki; T. Nakabayashi; Katsunori Ohnishi; Atsushi Fujisaku; Takao Koike
Hepatic diseases in systemic lupus erythematosus (SLE) are not rare, but liver biopsies of those cases are usually reported as chronic hepatitis or steroid-induced steatosis. We describe two unusual patients with active SLE who displayed liver dysfunction without inflammatory changes or associated with drug administration. A liver biopsy in case 1 showed massive hepatic cell damage resulting in acute hepatic failure. In case 2, the liver specimen revealed diffuse fatty degeneration without symptoms specific to liver dysfunction. No inflammatory cell infiltrate was observed in the liver tissue of either patient. After steroid pulse therapy (case 1) and the administration of 60 mg/day of prednisolone (case 2), liver function improved in parallel with the stabilization of the other manifestations of SLE. No other causes for liver damage except for SLE were observed in either case. Therefore it is supposed that the liver impairments in these cases were one manifestation of SLE.
Leukemia & Lymphoma | 1999
Takashi Tarumi; Ken-ichi Sawada; Kazuki Koizumi; Hina Takano; Yoshikazu Fukada; Mitsufumi Nishio; Teiji Fujie; Katsunori Ohnishi; Michifumi Kohno; Norihiro Sato; Sadayoshi Sekiguchi; Takao Koike
Fourteen consecutive patients with poor-risk aggressive NHL who at presentation had any one of four risk factors underwent response oriented induction chemotherapy and successive high-dose chemotherapy followed by autologous PBPC transplantation. After treatment with three cycles of conventional CHOP with G-CSF support (CHOP-G), the response was evaluated. For patients who achieved a complete remission (CR), an additional three cycles of CHOP-G were administered, while for partial response patients, another induction regimen including some non-cross-resistant agents was given; three cycles of VIPDexa-G (etoposide, ifosfamide, cisplatinum and dexamethasone) +/- two cycles of ENAP-G (mitoxantrone, etoposide, cytosine arabinoside and prednisone), were given. The scheduled induction chemotherapy, was followed by treatment with a high-dose cytoreductive regimen followed by autologous PBPC transplantation. After three cycles of CHOP-G, four patients (29%) achieved a CR, and 10 (71%) achieved a partial response (PR). When all scheduled induction therapy was completed, 10 patients (71%) had a CR. All 14 patients received high-dose therapy and obtained a complete hematologic recovery, except for one with a bone marrow relapse two months after transplantation. Evaluation of response after high-dose therapy showed 12 CRs (86%) which included three additional CRs, one PR, and one toxicity-related death. With a median follow-up of 12 months (range, 4 to 40), 12 are alive, with 11 in continuous first CR, and one relapse. The 2-year overall survival (OS) rate and event-free survival (EFS) rate are 77% and 79%, respectively, while the disease-free survival (DFS) rate is 92%. In conclusion, this pilot study suggests that response oriented induction chemotherapy and successive high-dose chemotherapy followed by autologous PBPC transplantation is commendable and can be associated with a high rate of remission and DFS for poor risk subjects with aggressive NHL.
Nihon Naika Gakkai Zasshi | 1985
Atsuchi Fujisaku; Akira Sagawa; Ichiro Watanabe; Kazuhide Tanimura; Masaya Mukai; Masato Shimizu; Ichiro Oki; Katsunori Ohnishi; Hoji Suzuki; Shoichi Nakagawa
広範な解離性胸腹部大動脈瘤の発症をみたMarfan症候群の1例を発端者とし,常染色体優性遺伝により伝播したMarfan症候群の多発家系を発見した.発端者は35才,女性で,解離性大動脈瘤,水晶体脱臼, arachnodactylyをはじめとする様々な骨格異常を有していた.さらに家系調査により一卵性双生児例や,幼児のMarfan症候群例をも発見しえた.本症候群患者の家系調査は症状の顕性化していない患者を発見する可能性があり,合併症に対する早期の対策の上からも重要と思われる.また,本症候群の一卵性双生児例は本邦第1例目と思われ,文献的考察を加え報告する.
Japanese Journal of Clinical Immunology | 1993
Tatsuya Atsumi; Atsushi Fujisaku; Nobutaka Ogura; Yoshiharu Amasaki; Katsunori Ohnishi; Akira Sagawa; Takao Koike
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine | 1986
Masaya Mukai; Akira Sagawa; Ichiro Watanabe; Kazuhide Tanimura; Masato Shimizu; Ichiro Oki; Katsunori Ohnishi; Atsushi Fujisaku; Suzuki H; Shoichi Nakagawa
Modern Rheumatology | 2011
Akira Sagawa; Atsushi Fujisaku; Katsunori Ohnishi; Masaya Mukai; Izumi Yasuda; Yoshiharu Amasaki; Masato Shimizu; Kenji Ichikawa; Hirofumi Ohsaki
Nihon Naika Gakkai Zasshi | 1986
Masaya Mukai; Akira Sagawa; Ichiro Watanabe; Kazuhide Tanimura; Masato Shimizu; Ichiro Oki; Katsunori Ohnishi; Atsushi Fujisaku; Shoichi Nakagawa
Japanese Journal of Clinical Immunology | 1994
Tsuyoshi Takeda; Akito Tsutsumi; Nobutaka Ogura; Satoshi Jodo; Yoshiharu Amasaki; Tohru Nakabayashi; Katsunori Ohnishi; Atsushi Fujisaku; Seiiti Kobayashi; Takao Koike
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine | 1988
Tohru Nakabayashi; Akira Sagawa; Atsushi Fujisaku; Isao Sakai; Ichiro Watanabe; Masaya Mukai; Izumi Yasuda; Katsunori Ohnishi; Shoichi Nakagawa